
    
      This is a Phase 4 Open-label Study to Evaluate the Treatment of Lupus Flares with H.P. Acthar
      Gel.

      The primary objective is to evaluate whether the addition of H.P. Acthar Gel to standard
      treatment of lupus will ameliorate the intensity of flares as measured by changes in SLEDAI
      score, Patient and Physician global assessments.

      The secondary objective is to evaluate any changes to the subjects BILAG scores and markers
      of inflammation, e.g. ESR and/or CRP.

      The Exploratory objective will determine the feasibility of a long-term double-blind study
      using H.P. Acthar Gel versus other usual treatments for lupus.
    
  